Evaluating the EVA1 Membrane Protein as a Target for Glioblastoma Therapy
Because EVA1 is not expressed in normal cells, there may be less toxicity when targeting it to eliminate glioblastoma-initiating cells.
FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC
A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.
Nimotuzumab Plus Image-Guided RT May Be Feasible in Older LACSCC Population
Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers
The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.
What is the Current State of ADC Treatment in EGFR-Amplified Glioblastoma?
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?
Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer
There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.
How do PDX and Computational Models Assist in the Development of ADCs?
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors
The Aliya PEF ablation procedure achieved local tumor control in 96% of patients and was well-tolerated with no delays to SOC therapy.
Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer
Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.
Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up
Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
Results from the phase 3 COMPETE trial demonstrated that 177Lu-edotreotide improved PFS and ORR compared with everolimus in patients with GEP-NETs.
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.
When Are Less Potent Payloads More Effective Than Ultra Potent Payloads in ADCs?
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
FOG-001 Earns FDA Fast Track Designation in Desmoid Tumors
Data from a phase 1/2 trial demonstrate the potential antitumor activity of FOG-001 in patients with desmoid tumors.
In Response: Why the Passing of H.R.2541 Is Needed
Ron Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.
FDA Approves Ziftomenib in R/R NPM1-Mutated Acute Myeloid Leukemia
Clinical data from the phase 1b/2 KOMET-001 trial support the agency’s approval of ziftomenib in this patient population.
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.
Optimizing Preclinical Data for Seamless Translation in Clinical Scenarios
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC
DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.
Leveraging Multidisciplinary Collaboration to Enhance RPT Benefit in Cancer
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The Promega OncoMate MSI Dx Analysis System was previously approved to identify Lynch syndrome in patients with CRC.
Novel Anti-CD5 Therapy Earns FDA RMAT Designation in T-Cell Lymphoma
Preliminary findings from a phase 2 trial show clinical activity with MB-105 in patients with relapsed/refractory T-cell lymphoma.
Nivolumab/Ipilimumab Improves Real-World Melanoma Outcomes Vs Pembrolizumab
At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.
Detalimogene Exhibits Improved Response Rate in BCG-Unresponsive NMIBC
Most patients with BCG-unresponsive NMIBC treated with detalimogene voraplasmid did not experience TRAEs, and only 1.6% experienced dose interruptions.
